Article

Continuous Infusion of Endostar Combined with Chemotherapy in Patients with Advanced or Recurrent Mucosal Melanoma: A Real-World Cohort Study

2021-07-30

Abstract excerpt

<h4>Background: </h4> Mucosal melanoma is rare and has distinct clinical and genetic features. Even with advances in targeted and immune therapy, the survival of patients with advanced or recurrent mucosal melanomas remains poor. The standard treatment remains controversial and we conducted this real-world study aimed to test continuous intravenous Endostar infusion plus chemotherapy in this population in the firs...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1a5981d7-e002-56af-8583-82af84f8f704
DOI: 10.21203/rs.3.rs-651881/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Continuous Infusion of Endostar Combined with Chemotherapy in Patients with Advanced or Recurrent Mucosal Melanoma: A Real-World Cohort StudyDOI 10.21203/rs.3.rs-651881/v1Read

Candidate therapeutic agents in a newly established triple wild‐type mucosal melanoma cell lineSemantic proximity Read

Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.Semantic proximity Read

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.Semantic proximity Read

Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.Semantic proximity Read

Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment.Semantic proximity Read

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)Semantic proximity Read

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaSemantic proximity Read

Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunitySemantic proximity Read

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read

Primary melanoma of the gastrointestinal tract.Semantic proximity Read

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read